Amendment_No._1_-_FBO.pdf

AMENDMENT OF SOLICITATION

Solicitation Number: HHS-NIH-NIAID-DMID-NIHAI2017088 Amendment Number: 1

AMENDMENT ONE (1)

Issued by: National Institute of Allergy and Infectious Diseases (NIAID)

Office of Acquisitions, MSC 9821 5601 Fishers Lane Rockville, MD 20852

Solicitation Number: HHS-NIH-NIAID-DMID-NIHAI2017088

Date of Solicitation Issuance: March 16, 2017

Date of Amendment No.1 Issuance: March 28, 2017

Number of Pages: 2 Pages

NIAID Point of Contact: PRIMARY:

Jason Aroz, Contract Specialist Email: Jason.Aroz@nih.gov Phone: 301-761-7468

SECONDARY:

George Kennedy, Contracting Officer Email: kennedyg@mail.nih.gov Phone: 240-669-5170

The hour and date specified for receipt of Offers remains unchanged, 4:30 PM Eastern Prevailing Time on April 17, 2017.

Offerors MUST acknowledge receipt of the amendment by Amendment number(s) and date of the amendment.

FAILURE OF YOUR ACKNOWLEDEMENT TO BE RECEIVED AT THE PLACE

DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE

SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.

Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.

mailto:Jason.Aroz@nih.gov mailto:kennedyg@mail.nih.gov

Purpose of Solicitation Amendment:

The purpose of Amendment No. 1 is to respond to questions received regarding this solicitation.

Below is the Government’s responses to questions received:

1. Question: The solicitation notes that LC‐MS/MS protocols may be available for some compounds but not available for all. Is it known how many total compounds would require LC‐MS/MS method development?

Answer: NIAID cannot provide an estimate for the number of requests that would require LC‐MS/MS method development. As this requirement is for a firm-fixed-price contract, NIAID requires a single price for the pharmacokinetic (PK) study type regardless of whether new methods need to be developed. Offerors must make their own decisions regarding price for the PK study, balancing cost and risk.

2. Question: Is it necessary to develop a proposal for each assessment type or only for the "Study Type" of interest? For example, can an offeror submit a proposal for only "1.

Minimal Inhibitory Concentration (MIC) Determination" and "2. Efficacy Assessment"? Or should the proposal include a plan for all study types?

Answer: NIAID requires that offerors demonstrate the ability to perform all study types (and to show documentation of that ability, as described). Offerors may subcontract those tasks if the primary lab does not possess the requisite capability, but offerors must include a commitment letter from the subcontractor detailing: (a) the subcontractors willingness and ability to perform as a subcontractor for specific duties; (b) what priority the work will be given and how it will relate to other work; (c) the amount of time and facilities available to this project; (d) information on their cognizant field audit offices; (e) how rights to publications and patents are to be handled; and (f) a complete price proposal in the same format as the offeror's price proposal.

PLEASE NOTE: In the questions/responses above, specific organizational names have been removed or replaced where possible as well as other minor adjustments.

ALL OTHER TERMS AND CONDITIONS OF THIS SOLICITATION REMAIN

UNCHANGED.

End of Amendment 1